Refractory Palmoplantar Pustulosis Successfully Treated with JAK Inhibitor Tofacitinib: A Case Series
Qingqing Xu,Xiaochen Wang,Anbo Yang,Guo Wei
DOI: https://doi.org/10.2147/IDR.S421299
2023-08-10
Infection and Drug Resistance
Abstract:Qingqing Xu, 1 Xiaochen Wang, 2 Anbo Yang, 3 Guo Wei 1 1 Department of Dermato-Venereology, the Second Hospital of Shandong University, Jinan, 250033, People's Republic of China; 2 Clinical Laboratory of Qingdao Municipal Hospital, Qingdao, 266000, People's Republic of China; 3 Department of Dermato-Venereology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, People's Republic of China Correspondence: Anbo Yang; Guo Wei, Email ; Background: Palmoplantar pustulosis (PPP) is a common chronic and recurrent skin disease of the palms and soles with significant pain, mental distress, and functional disability. PPP is challenging to treat and usually requires prolonged management. Therapy resistance and frequent relapse discourages patients from follow-up. No unified standard and no published therapeutic guidelines have yet been defined on PPP treatment. In general, all therapeutic options known for autoimmune diseases, psoriasis in particular, have been tested in PPP. Tofacitinib, an oral JAK inhibitor, has been approved for the treatment of rheumatoid arthritis and shows promise in the treatment of moderate-to-severe plaque psoriasis. However, no clinical trials or case reports have been conducted to confirm the efficacy of tofacitinib in palmoplantar pustulosis. Methods: Six in total with 6 PPP patient, aged 42– 58 years were recruited according to the inclusion and exclusion criteria. Patient characteristics, including triggering factors, concomitant diseases, and previous therapeutic drugs, were investigated. All patients experienced a lack of response to topical drugs and at least one systemic agent. During treatment, visits were scheduled at the start of treatment and at 2, 4, and 12 weeks, and efficacy was assessed using the PPP ASI and PPP PGA. Results: Our six patients showed an excellent response to tofacitinib as all patients did achieve at least 50% reduction and half of our patients with more than 80% reduction in PPPASI after 4 weeks treatment; at week 12, 5 (83.3%) patients had 80% reduction in PPPASI with no serious adverse events were reported. Conclusion: The JAK inhibitor tofacitinib is a promising treatment for refractory palmoplantar pustulosis that requires further clinical observation and research. Keywords: refractory palmoplantar pustulosis, tofacitinib, palmoplantar pustular psoriasis area and severity index Palmoplantar pustulosis (PPP) is a common chronic and recurrent dermatosis characterized by aseptic pustules on the palms and soles, which often causes disproportionate pain, pruritus, and functional disability. The prevalence of PPP ranges from 0.01 to 0.05%. 1 The mean patient age ranged from 40 to 58 years. 2 Smoking is one of the important inducing factor 2 in PPP, and tonsillar streptococcal 3 or dental infections 4 may exacerbate PPP. Other triggering factors, including dental metal allergies 5 and some drugs, especially anti-TNF agents 6 may induce or exacerbate PPP. PPP usually occurs concomitantly with various other diseases. Autoimmune thyroid disease is often observed in PPP patients. 7 Obesity (BMI > 25 mg/m2), T2DM, hyperlipidemia, allergic diseases (such as asthma, atopic dermatitis, and rhinitis allergica) and joint pain frequently accompanies PPP lesions. 7,8 PPP is challenging to treat and usually requires prolonged management. Therapy resistance and frequent relapse discourage patients from follow-up. To date, no therapeutic standards or published guidelines have been defined for PPP treatment. In general, all known therapeutic options for autoimmune diseases, psoriasis in particular, have been tested in patients with PPP. Therapeutic recommendations for PPP are mainly based on case reports and dermatologist' own long-term clinical experience. Topically potent glucocorticosteroids, retinoids, vitamin D derivatives, keratolytic agents and emollients are first-line agents for PPP treatment. 9 In practice, however, refractory or severe PPP patients often require systemic therapy. Current systemic treatment options include retinoids, immunosuppressant (such as methotrexate, cyclosporine and mofetil) and biological agents that are approved for psoriasis Vulgaris. 9 Janus kinases (JAKs) family consisting of 4 members: JAK1, JAK2, JAK3, and TYK, belongs to non-receptor tyrosine protein kinases. When cytokines (IL-6, IL-22, IL-23, or IFN-γ) bind to their receptors, JAKs are recruited to phosphorylate and activate STAT family proteins. Activated STAT proteins undergo dimerization and translocate into the nucleus to modulate gene expression. 10 Dysregulati -Abstract Truncated-
pharmacology & pharmacy,infectious diseases